Form DEFA14A DiaMedica Therapeutics
Tweet
Share
E-mail
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE
SECURITIES EXCHANGE ACT OF 1934
Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐
Check the appropriate box:
|
☐ |
Preliminary Proxy Statement |
|
☐ |
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
☐ |
Definitive Proxy Statement |
|
☒ |
Definitive Additional Materials |
|
☐ |
Soliciting Material Pursuant to §240.14a-11(c) or §240.14a-2 |
|
DIAMEDICA THERAPEUTICS INC. |
|
(Name of Registrant as Specified In Its Charter) |
Payment of Filing Fee (Check the appropriate box):
|
☒ |
No fee required |
|
☐ |
Fee paid previously with preliminary materials |
|
☐ |
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MixRoute Confirms Claude Fable 5 Support, Giving Developers One-Key Access to Both Fable 5 and GPT-5.6
- CORRECTS AND REPLACES: Simply Solventless Provides Update on Filing of 2025 Annual Financial Statements and Related Management's Discussion and Analysis and Management Cease Trade Order
- CG Semi Commences Commercial Production at Its G1 OSAT Facility in Sanand, Gujarat
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
